These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2124 related articles for article (PubMed ID: 29405201)

  • 1. Targeting the IL-6/JAK/STAT3 signalling axis in cancer.
    Johnson DE; O'Keefe RA; Grandis JR
    Nat Rev Clin Oncol; 2018 Apr; 15(4):234-248. PubMed ID: 29405201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The IL-6/JAK/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer (Review).
    Wang SW; Sun YM
    Int J Oncol; 2014 Apr; 44(4):1032-40. PubMed ID: 24430672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.
    Bharadwaj U; Kasembeli MM; Robinson P; Tweardy DJ
    Pharmacol Rev; 2020 Apr; 72(2):486-526. PubMed ID: 32198236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The tyrosine phosphatase SHP2 increases robustness and information transfer within IL-6-induced JAK/STAT signalling.
    Fiebelkow J; Guendel A; Guendel B; Mehwald N; Jetka T; Komorowski M; Waldherr S; Schaper F; Dittrich A
    Cell Commun Signal; 2021 Sep; 19(1):94. PubMed ID: 34530865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia.
    Bonetto A; Aydogdu T; Jin X; Zhang Z; Zhan R; Puzis L; Koniaris LG; Zimmers TA
    Am J Physiol Endocrinol Metab; 2012 Aug; 303(3):E410-21. PubMed ID: 22669242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting JAK kinase in solid tumors: emerging opportunities and challenges.
    Buchert M; Burns CJ; Ernst M
    Oncogene; 2016 Feb; 35(8):939-51. PubMed ID: 25982279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The JAK/STAT3 axis: A comprehensive drug target for solid malignancies.
    Huynh J; Etemadi N; Hollande F; Ernst M; Buchert M
    Semin Cancer Biol; 2017 Aug; 45():13-22. PubMed ID: 28647610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zelnorm, an agonist of 5-Hydroxytryptamine 4-receptor, acts as a potential antitumor drug by targeting JAK/STAT3 signaling.
    Zhang L; Song Q; Zhang X; Li L; Xu X; Xu X; Li X; Wang Z; Lin Y; Li X; Li M; Su F; Wang X; Qiu P; Guan H; Tang Y; Xu W; Yang J; Zhao C
    Invest New Drugs; 2020 Apr; 38(2):311-320. PubMed ID: 31087223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
    Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
    Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revisiting STAT3 signalling in cancer: new and unexpected biological functions.
    Yu H; Lee H; Herrmann A; Buettner R; Jove R
    Nat Rev Cancer; 2014 Nov; 14(11):736-46. PubMed ID: 25342631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brevilin A, a novel natural product, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells.
    Chen X; Du Y; Nan J; Zhang X; Qin X; Wang Y; Hou J; Wang Q; Yang J
    PLoS One; 2013; 8(5):e63697. PubMed ID: 23704931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels.
    Xu L; Chen X; Shen M; Yang DR; Fang L; Weng G; Tsai Y; Keng PC; Chen Y; Lee SO
    Mol Oncol; 2018 Mar; 12(3):269-286. PubMed ID: 28865178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
    Lai SY; Johnson FM
    Drug Resist Updat; 2010 Jun; 13(3):67-78. PubMed ID: 20471303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-6 mediates the signal pathway of JAK-STAT3-VEGF-C promoting growth, invasion and lymphangiogenesis in gastric cancer.
    Zhao G; Zhu G; Huang Y; Zheng W; Hua J; Yang S; Zhuang J; Ye J
    Oncol Rep; 2016 Mar; 35(3):1787-95. PubMed ID: 26750536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-regulation of microRNA-9 leads to activation of IL-6/Jak/STAT3 pathway through directly targeting IL-6 in HeLa cell.
    Zhang J; Jia J; Zhao L; Li X; Xie Q; Chen X; Wang J; Lu F
    Mol Carcinog; 2016 May; 55(5):732-42. PubMed ID: 25809226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STAT3/5 Inhibitors Suppress Proliferation in Bladder Cancer and Enhance Oncolytic Adenovirus Therapy.
    Hindupur SV; Schmid SC; Koch JA; Youssef A; Baur EM; Wang D; Horn T; Slotta-Huspenina J; Gschwend JE; Holm PS; Nawroth R
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32046095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silencing of
    Zhang P; Li Z; Yang G
    Int J Mol Med; 2021 Dec; 48(6):. PubMed ID: 34713300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer.
    Zhang N; Zeng Y; Du W; Zhu J; Shen D; Liu Z; Huang JA
    Int J Oncol; 2016 Oct; 49(4):1360-8. PubMed ID: 27499357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SP2509, an inhibitor of LSD1, exerts potential antitumor effects by targeting the JAK/STAT3 signaling.
    Zhen H; Zhang X; Zhang L; Zhou M; Lu L; Wu L; He N; Wang J; Li R; Guo Y
    Acta Biochim Biophys Sin (Shanghai); 2021 Jul; 53(8):1098-1105. PubMed ID: 34169322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic variants in IL-6/JAK/STAT3 pathway and the risk of CRC.
    Wang S; Zhang W
    Tumour Biol; 2016 May; 37(5):6561-9. PubMed ID: 26638167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 107.